Read by QxMD icon Read


Shinichiro Kashiwagi, Gen Tsujio, Yuka Asano, Wataru Goto, Koji Takada, Katsuyuki Takahashi, Tamami Morisaki, Hisakazu Fujita, Tsutomu Takashima, Shuhei Tomita, Masahiko Ohsawa, Kosei Hirakawa, Masaichi Ohira
BACKGROUND: Recently, the concepts of progression due to pre-existing lesions (PPL) and progression due to new metastasis (PNM) have been proposed to differentiate the progression types of treatment-resistant cancers. Previously, the differences between these two progression types did not affect the determination of treatment strategies since both PPL and PNM are classified as progressive disease based on the response evaluation criteria in solid tumors (RECIST) diagnostic criteria. On the other hand, tumor infiltrating lymphocytes (TILs) are effective when used as indicators for monitoring the immune tumor microenvironment (iTME) in the cancer host, and TILs play an important role as biomarkers in predicting prognosis and therapeutic effects...
March 9, 2018: Journal of Translational Medicine
Yasuko Kikuchi, Yoshihiro Uchida, Kazuo Shirakawa, Hajime Kanauchi, Takayoshi Niwa, Kotoe Nishioka, Keiichirou Tada, Masanori Hashimoto, Hidemitsu Yasuda, Ryoko Sugiura, Hidetaka Kawabata, Yasuyuki Seto, Toshihisa Ogawa
AIM: This multicenter, observational study aimed to investigate the survival benefit of eribulin as well as that of taxane-based regimens in Japanese patients with metastatic breast cancer (MBC) in a real-world setting. METHODS: This study enrolled women with MBC who received eribulin or taxane-based regimens with or without bevacizumab in routine clinical practice from July 2011 to March 2014. Patients were followed until September 2015. The primary endpoint was overall survival (OS)...
March 1, 2018: Asia-Pacific Journal of Clinical Oncology
Frederik Marmé, Carlos Gomez-Roca, Kristina Graudenz, Funan Huang, John Lettieri, Carol Peña, Zuzana Jirakova Trnkova, Jan Eucker
Combining sorafenib and eribulin mesylate may provide synergistic antitumor activities with limited overlapping toxicities. This phase 1b, open-label, dose-escalation study evaluated safety, pharmacokinetics, maximum tolerated dose/recommended phase 2 dose (MTD/RP2D), and preliminary efficacy of sorafenib plus standard-dose eribulin mesylate in patients with advanced, metastatic, or refractory tumors. Patients received sorafenib 200 mg twice daily (BID; n = 5), 600 mg/day (n = 8), and 400 mg BID (MTD; n = 27)...
February 21, 2018: Cancer Chemotherapy and Pharmacology
Nicholas F Dybdal-Hargreaves, April L Risinger, Susan L Mooberry
Microtubule targeting agents (MTAs) are some of the most effective anticancer drugs used to treat a wide variety of adult and pediatric cancers. Building evidence suggests that these drugs inhibit interphase signaling events and that this contributes to their anticancer actions. The effects of diverse MTAs were evaluated following a 2 hour incubation with clinically relevant concentrations to test the hypothesis that these drugs rapidly and differentially disrupt epithelial-to-mesenchymal transition (EMT)-related signaling...
January 19, 2018: Oncotarget
Panagiotis Koliou, Vasilios Karavasilis, Maria Theochari, Seth M Pollack, Robin L Jones, Khin Thway
Eribulin mesylate is a synthetic derivative of halichondrin B isolated from a marine sponge. Its mechanism of action is through microtubule inhibition, which is different from that of taxanes. Eribulin has been approved for the treatment of metastatic breast cancer and more recently for non-operable or metastatic liposarcoma in patients who have received prior anthracycline chemotherapy. The major side effects of eribulin are bone marrow suppression including neutropenia, leukopenia, anemia, and fatigue/weakness, which can be well managed...
2018: Cancer Management and Research
Shoichiro Ohtani, Takahiro Nakayama, Tetsuhiro Yoshinami, Ken-Ichi Watanabe, Fumikata Hara, Yasuaki Sagara, Hidetoshi Kawaguchi, Kenji Higaki, Nobuki Matsunami, Yoshie Hasegawa, Masato Takahashi, Makiko Mizutani, Takashi Morimoto, Masako Sato, Mitsuya Itoh, Satoshi Morita, Norikazu Masuda
BACKGROUND: This study aimed to investigate whether schedule modification is safe and effective in patients intolerant to the standard eribulin dose and schedule. METHODS: Patients with metastatic breast cancer (MBC) treated with both anthracycline and taxane and ≤ 3 prior regimens of chemotherapy for MBC received eribulin at the standard dose and schedule (1.4 mg/m2 on days 1 and 8 of a 21-day cycle) in the first cycle; change of dosing schedule (1.4 mg/m2 on days 1 and 15 of a 28-day cycle) was determined by change in neutrophil count, platelet count, aspartate aminotransferase, alanine aminotransferase, total bilirubin, serum creatinine, and non-hematological toxicity on day 8 of the first cycle or day 1 of the second cycle...
February 12, 2018: Breast Cancer: the Journal of the Japanese Breast Cancer Society
Mahesh Seetharam, Kantha R Kolla, Sant P Chawla
Eribulin is a structurally simplified, synthetic macrocyclic ketone analog of halichondrin B, which is a natural, polyether macrolide derived from marine sponges. Eribulin exerts its cytotoxicity by its unique microtubule dynamics inhibitory action. Eribulin was approved in 2010 by the US FDA as a third-line therapy for metastatic breast cancer patients previously treated with an anthracycline and a taxane. In 2016, it was approved for treatment of metastatic liposarcoma for patients who have progressed with anthracycline treatment...
February 7, 2018: Future Oncology
Takashi Katsumori, Hisami Ohshima, Hiromitsu Hamaguchi, Shinichi Yamamoto, Yukika Tsukamoto, Tomohiro Iwanaga, Susumu Ohkawara
A 50s-year-old woman underwent left partial mastectomy with axillary lymphadenectomy for breast cancer. Histological examination indicated invasive ductal carcinoma, pT1c, pN0, Stage I , ly(+), ER(+), PgR(+). She received adjuvant therapy with tamoxifen and 50 Gy of irradiation to the residual breast. Four years after mastectomy, she was found to have left Rotter lymph node metastasis; then, anastrozole was administered instead of tamoxifen. Nine months later, she was found to have liver metastasis. Immunohistostaining revealed that the breast cancer was HER2-positive; she received AC followed by paclitaxel(PTX)with trastuzumab(T), and achieved complete response(CR)...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Rama Adikrisna, Tetsuo Sugishita, Hirotomo Takahara, Satoru Kakuta, Yoshiki Murase, Yuichiro Watanabe, Masaru Udagawa
A 51-year-old man came to our department because of a large abdominal mass. CT, MRI, and sonography revealed a large tumor adjacent to the retroperitoneal area. A resection was performed, and histologically we confirmed the diagnosis as a leiomyosarcoma originating from the retroperitoneum. Six years after the initial surgery, the patient came to our outpatient department with a complaint of nausea. A relatively large tumor was seen on a CT scan that was causing obstruction of the duodenum. Another surgery was performed with the final diagnosis as a recurrence of the leiomyosarcoma...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Katsunori Narahara, Tomomi Abe, Kenji Katsumata, Akihiko Tsuchida
A 79-year-old woman presented with a chief complaint of a palpated tumor on her right axilla. The right breast tumor size was 18mm and the axillary lymph node size was 30 mm, as detected with ultrasonography. Pathological findings indicated the presence of an ER(-), Pg R(-), HER2-negative apocrine carcinoma. The presence of axillary lymph node metastasis was diagnosed from the apocrine carcinoma. Eribulin(1.5mg)was administered 3 times before surgery. Tumors were significantly reduced. The Bt+Ax(Patey procedure)dissection was performed until Level 2...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Hirotaka Furuke, Katsumi Shimomura, Chikage Kato, Kazuya Takabatake, Takuma Kishimoto, Sachie Tanaka, Tatsuya Kumano, Syuuhei Komatsu, Kenichirou Imura, Takeshi Kubota, Jun Ikeda, Fumihiro Taniguchi, Yasuhiro Shioaki
Retroperitoneal liposarcoma is a relatively rare tumor. The only established therapy is surgical resection and the tumor often recurs. This paper deals with a case of a retroperitoneal liposarcoma in which frequent surgical resections for recurrent tumors have provided relatively long-term survival for the patient. The patient was a 70-year-old woman who had undergone surgical resection for a right retroperitoneal tumor. The pathological diagnosis was dedifferentiated liposarcoma. Thereafter she experienced frequent recurrences which required 3 surgical resections...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Setsuko Yoshioka, Shigeyuki Hojo, Yasuhiro Toyoda, Yoshiichi Maeura
A 48-year-old woman who observed swelling and erosion in her left breast was diagnosed with locally advanced, ERnegative, HER2-positive breast cancer with de novo liver metastasis, T4cN1M1, Stage IV . She underwent primary systemic therapy with weekly paclitaxel, and pertuzumab and trastuzumab every 3 weeks. The tumor responded remarkably with 57.0% reduction in 5 weeks of treatment. Because of an anaphylactic shock to paclitaxel in day 8, exchanging to eribulin was considered less toxic than taxane, and was continued for 8 cycles until local relapse...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Natsuko Tanaka, Kaoru Ogura, Akinori Hattori, Hiroaki Inoue, Hiroko Yukawa, Shiho Sakaguchi, Aya Matsuoka, Asaka Kodera, Yoshihiko Naritaka, Akira Hirano
PATIENTS AND METHODS: This retrospective observational study contains advanced or metastatic breast cancer female patients who pretreated with anthracycline and/or taxane received eribulin(ERI)mesylate. The primary endpoint was the progressionfree survival(PFS)and secondary endopoints were objective response rate(ORR), clinical benefit rate(CBR), overall survival (OS), and post-progression survival(PPS). RESULTS: A total of 32 patients underwent chemotherapy cycles(median 3; range 1-9 cycles)...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Nobuko Ogura, Shoji Tsunekawa, Asami Okabe, Takashi Sugimoto, Kazuhiro Nishiyama, Yu Oshima, Youhei Hosoda, Hidenori Kiyochi, Izumi Komoto, Yoshiro Taki, Utae Katsushima, Kazuhiro Yanagihara, Jun Kawai
We report a case of triple negative spindle cell carcinoma of the breast, responsive to irinotecan chemotherapy. A 49-year old woman who had a tumor in the chest wall with a skin ulcer visited our hospital. After being diagnosed with triple negative spindle cell carcinoma of the breast, she underwent surgery, adjuvant chemotherapy, and radiation at the other hospital. Fourteen months after the surgery, she developed an ipsilateral breast tumor as a result of local recurrence. Since eribulin and paclitaxel plus bevacizumab chemotherapies were not effective, she was transferred to our hospital, and we administered irinotecan as third-line chemotherapy...
December 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Ling Peng, Yun Hong, Xianghua Ye, Peng Shi, Junyan Zhang, Yina Wang, Qiong Zhao
Background: Eribulin is a microtubule inhibitor, which is approved for the treatment of breast cancer. Peripheral neuropathy has been reported in the studies of eribulin, but the incidence and relative risk (RR) of eribulin-associated peripheral neuropathy varied greatly in cancer patients. The purpose of this meta-analysis was to determine the overall incidence and RR of eribulin-associated peripheral neuropathy in cancer patients. Materials and Methods: Pubmed database and Embase and abstracts presented at the American Society of Clinical Oncology (ASCO) meetings were systematically reviewed for primary studies...
December 19, 2017: Oncotarget
Xavier Pivot, Seock Ah Im, Matthew Guo, Frederik Marmé
This post hoc subgroup analysis of a large phase 3 study compared the efficacy and safety of eribulin versus capecitabine in patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who received second-line treatment. In the phase 3 study, women with advanced/metastatic breast cancer and ≤ 3 prior chemotherapies were randomized 1:1 to eribulin mesilate 1.4 mg/m2 intravenously on days 1 and 8, or twice-daily oral capecitabine 1.25 g/m2 on days 1-14 (21-day cycles)...
January 4, 2018: Breast Cancer: the Journal of the Japanese Breast Cancer Society
Cristina P Rodriguez, Renato G Martins, Christina Baik, Laura Q Chow, Rafael Santana-Davila, Bernardo H Goulart, Sylvia Lee, Keith D Eaton
BACKGROUND: This study examined the microtubule inhibitor eribulin in recurrent/metastatic salivary gland cancers (RMSGCs), a disease where no therapeutic standard exists. METHODS: This phase II clinical trial treated patients with progressive recurrent/metastatic salivary gland cancers with eribulin 1.4 mg/m2 i.v. on days 1 and 8 of a 21-day cycle until disease progression/unacceptable toxicities. The primary endpoint was the Response Evaluation Criteria in Solid Tumors (RECIST) version 1...
December 28, 2017: Head & Neck
Renaud Sabatier, Véronique Diéras, Xavier Pivot, Etienne Brain, Henri Roché, Jean-Marc Extra, Audrey Monneur, Magali Provansal, Carole Tarpin, François Bertucci, Patrice Viens, Christophe Zemmour, Anthony Gonçalves
Purpose: Eribulin is approved for advanced breast cancers refractory to anthracyclines and taxanes. Efficacy according to sensitivity to previous therapies has been poorly explored. Materials and Methods: Safety data were collected prospectively and we retrospectively collected efficacy data from the five French centres that participated in the Eribulin E7389-G000-398 expanded access program. Our main objectives were exploration of safety and analysis of eribulin efficacy (progression-free survival [PFS] and overall survival [OS]) according to sensitivity to the last microtubule-inhibiting agent administered...
December 28, 2017: Cancer Research and Treatment: Official Journal of Korean Cancer Association
Shinichiro Kashiwagi, Yuka Asano, Wataru Goto, Koji Takada, Katsuyuki Takahashi, Takaharu Hatano, Sayaka Tanaka, Tsutomu Takashima, Shuhei Tomita, Hisashi Motomura, Masahiko Ohsawa, Kosei Hirakawa, Masaichi Ohira
BACKGROUND/AIM: Eribulin mesylate (eribulin) is currently used for the treatment of locally advanced or metastatic breast cancer (MBC). It is a cytotoxic agent with unique mechanisms that suppress the epithelial-mesenchymal transition (EMT) of cancer cells and promote tumor vascular remodeling. In this study, we investigated the expression of markers for EMT and hypoxia in sets of clinical specimens collected before and after eribulin treatment to verify its unique mechanisms. PATIENTS AND METHODS: The expression of markers for EMT and cellular hypoxia [E-cadherin, N-cadherin, vimentin, and carbonic anhydrase 9 (CA9)] was examined immunohistochemically in MBC tissues collected from 20 patients before and after chemotherapy with either eribulin (n=10) or paclitaxel (n=10)...
January 2018: Anticancer Research
Yevette McGovern, Charlie D Zhou, Robin L Jones
Liposarcoma is one of the most common subtypes of soft-tissue sarcoma and consists of three main subtypes, of which well-differentiated liposarcoma and dedifferentiated liposarcoma account for 40-45%. The current mainstay of systemic treatment for patients with metastatic or unresectable disease remains doxorubicin with or without ifosfamide in the first-line setting. Recently, eribulin and trabectedin have been approved by the US Food and Drug Administration for recurrent liposarcomas and progress in molecular characterization of these tumors has opened up new and potential novel treatment targets...
2017: Frontiers in Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"